Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Press releaseGlobeNewswire· July 29, 2026
RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET
View original at globenewswire.com“a record $563,000 of sales in the first quarter of 2026”
Ce que nous avons tiré de cette source
The claims Via News extracted from this document. We point to the source; we don't replace it.
RenovoRx anticipates full enrollment in the TIGeR-PaC trial in the very near term and final data readout in mid-to-late 2027.
60% confidenceRenovoRx management will discuss the Company's growing revenues from commercial sales of RenovoCath as a standalone drug-delivery device, as well as increased RenovoCath adoption at high-volume U.S. cancer centers and a broader base of repeat orders from existing customers.
60% confidence
